Analysts See $-0.37 EPS for Aeterna Zentaris Inc. (AEZS)

March 20, 2018 - By Marie Mckinney

 Analysts See $ 0.37 EPS for Aeterna Zentaris Inc. (AEZS)

Analysts expect Aeterna Zentaris Inc. (NASDAQ:AEZS) to report $-0.37 EPS on March, 21.They anticipate $0.34 EPS change or 47.89 % from last quarter’s $-0.71 EPS. After having $-0.44 EPS previously, Aeterna Zentaris Inc.’s analysts see -15.91 % EPS growth. The stock decreased 2.37% or $0.04 during the last trading session, reaching $1.65. About 34,818 shares traded. Aeterna Zentaris Inc. (NASDAQ:AEZS) has declined 74.02% since March 20, 2017 and is downtrending. It has underperformed by 90.72% the S&P500.

Aeterna Zentaris Inc. (NASDAQ:AEZS) Ratings Coverage

Among 3 analysts covering Aeterna Zentaris Inc. (NASDAQ:AEZS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aeterna Zentaris Inc. has $12.0 highest and $1 lowest target. $3.50’s average target is 112.12% above currents $1.65 stock price. Aeterna Zentaris Inc. had 11 analyst reports since August 18, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, December 2 by H.C. Wainwright. Maxim Group maintained it with “Buy” rating and $400 target in Friday, August 11 report. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, November 24. Maxim Group maintained the shares of AEZS in report on Wednesday, July 19 with “Buy” rating. The firm has “Buy” rating by Maxim Group given on Monday, November 23. On Wednesday, July 5 the stock rating was maintained by H.C. Wainwright with “Buy”. Canaccord Genuity upgraded the stock to “Buy” rating in Monday, November 9 report. As per Tuesday, January 17, the company rating was maintained by Maxim Group. The firm earned “Buy” rating on Wednesday, November 29 by H.C. Wainwright. Maxim Group maintained the shares of AEZS in report on Friday, June 30 with “Buy” rating.

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company has market cap of $27.32 million. The company's product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency. It currently has negative earnings. It is also developing an LHRH-disorazol Z conjugate, which is in pre-clinical development in oncology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.